These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33718174)

  • 41. Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.
    Freeman M; Betts KA; Jiang S; Du EX; Gupte-Singh K; Lu Y; Rao S; Shoushtari AN
    Adv Ther; 2019 Oct; 36(10):2783-2796. PubMed ID: 31440980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
    Weber J; Mandala M; Del Vecchio M; Gogas HJ; Arance AM; Cowey CL; Dalle S; Schenker M; Chiarion-Sileni V; Marquez-Rodas I; Grob JJ; Butler MO; Middleton MR; Maio M; Atkinson V; Queirolo P; Gonzalez R; Kudchadkar RR; Smylie M; Meyer N; Mortier L; Atkins MB; Long GV; Bhatia S; Lebbé C; Rutkowski P; Yokota K; Yamazaki N; Kim TM; de Pril V; Sabater J; Qureshi A; Larkin J; Ascierto PA;
    N Engl J Med; 2017 Nov; 377(19):1824-1835. PubMed ID: 28891423
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ipilimumab/nivolumab-induced pseudolymphoma in a patient with malignant melanoma.
    Ayoubi N; Haque A; Vera N; Ma S; Messina J; Khushalani N; Seminario-Vidal L
    J Cutan Pathol; 2020 Apr; 47(4):390-393. PubMed ID: 31677178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
    Gao CA; Weber UM; Peixoto AJ; Weiss SA
    J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials.
    Menshawy A; Eltonob AA; Barkat SA; Ghanem A; Mniesy MM; Mohamed I; Abdel-Maboud M; Mattar OM; Elfil M; Bahbah EI; Elgebaly A
    Melanoma Res; 2018 Oct; 28(5):371-379. PubMed ID: 29957656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
    Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
    J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Health-related quality of life results from the phase III CheckMate 067 study.
    Schadendorf D; Larkin J; Wolchok J; Hodi FS; Chiarion-Sileni V; Gonzalez R; Rutkowski P; Grob JJ; Cowey CL; Lao C; Wagstaff J; Callahan MK; Postow MA; Smylie M; Ferrucci PF; Dummer R; Hill A; Taylor F; Sabater J; Walker D; Kotapati S; Abernethy A; Long GV
    Eur J Cancer; 2017 Sep; 82():80-91. PubMed ID: 28651159
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
    Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
    J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cystadenocarcinoma (papillary cystadenocarcinoma) of the submandibular gland.
    Harimaya A; Somekawa Y; Sasaki M; Ohuchi T
    J Laryngol Otol; 2006 Dec; 120(12):1077-80. PubMed ID: 16995970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
    Weber J; Gibney G; Kudchadkar R; Yu B; Cheng P; Martinez AJ; Kroeger J; Richards A; McCormick L; Moberg V; Cronin H; Zhao X; Schell M; Chen YA
    Cancer Immunol Res; 2016 Apr; 4(4):345-53. PubMed ID: 26873574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of shortened infusion times for combined ipilimumab and nivolumab.
    Gassenmaier M; Lipp HP; Scheu A; Wagner NB; Kofler L; Mueller A; Doecker D; Eigentler TK; Garbe C; Forschner A
    Cancer Immunol Immunother; 2018 Jan; 67(1):135-140. PubMed ID: 28988363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma; Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy; Genetic Basis for Clinical Response to CTLA-4 Blockade; Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma; Nivolumab plus Ipilimumab in Advanced Melanoma; Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma; Hepatotoxicity with Combination of Vemurafenib and Ipilimumab.
    N Engl J Med; 2018 Nov; 379(22):2185. PubMed ID: 31442371
    [No Abstract]   [Full Text] [Related]  

  • 53. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
    Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
    Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.
    Warner BM; Baer AN; Lipson EJ; Allen C; Hinrichs C; Rajan A; Pelayo E; Beach M; Gulley JL; Madan RA; Feliciano J; Grisius M; Long L; Powers A; Kleiner DE; Cappelli L; Alevizos I
    Oncologist; 2019 Sep; 24(9):1259-1269. PubMed ID: 30996010
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
    Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.
    van Bussel MTJ; Beijnen JH; Brandsma D
    BMC Cancer; 2019 May; 19(1):519. PubMed ID: 31146733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
    Mason R; Dearden HC; Nguyen B; Soon JA; Smith JL; Randhawa M; Mant A; Warburton L; Lo S; Meniawy T; Guminski A; Parente P; Ali S; Haydon A; Long GV; Carlino MS; Millward M; Atkinson VG; Menzies AM
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):358-365. PubMed ID: 31587511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy.
    Shi DD; Arnaout O; Bi WL; Buchbinder EI; Cagney DN; Insco ML; Liu D; Schoenfeld JD; Aizer AA
    World Neurosurg; 2020 Jul; 139():226-231. PubMed ID: 32330622
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
    Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
    Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.